Rochester-led study leads to recommendation for use of heart failure treatment nationwide

A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronisation therapy defibrillator (CRT - D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Centre, be approved for use in patients with mild heart failure in the United States...

Read the whole article on

More from